Active Stocks: GTx, Vitamin Shoppe, Synch Tech, Perrigo May 8th

GTx, Inc. (NASDAQ:GTXI): GTx announced that the FDA removed its Full Clinical Hold on the company’s Investigational New Drug application for Capesaris following the review by the FDA of the Company’s complete response and its new Phase II clinical protocol. GTx plans to initiate during the third quarter this Phase II open label clinical study of 75 men with metastatic castration resistant prostate cancer to test three lower doses of Capesaris sequentially in cohorts of 25 patients each. Shares of GTx, Inc. are trading 14.19% higher today.

Vitamin Shoppe, Inc. (NYSE:VSI): Reports Q1 revenue $248.1M versus consensus $239.71M. Shares of Vitamin Shoppe, Inc. are trading 16.76% higher today.

Synchronoss Technologies, Inc. (NASDAQ:SNCR): Reiterates 2012 revenue outlook $280M-$290M, consensus $287M. The company sees 2012 gross margin at the high end of 60%-61%. Guidance was issued on last night’s earnings conference call. Shares of Synchronoss Technologies, Inc. are trading 23.85% lower today.

Perrigo Company (NASDAQ:PRGO): The adjustment in revenue guidance is due to a historically mild cough/cold and flu season. FY12 revenue consensus of $3.25B. Shares of Perrigo Company are trading 6% lower today.

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.